Hormones & Sexual Function: A Clinical Guide

The core principle: Hormones modulate desire, arousal, and sexual response, and correcting a documented deficiency can help. But as Dr. Greenleaf frames it in Empire’s training, hormones are a tool, not the answer. Even with hormone therapy, if stress, sleep, vascular health, medications, and relationship factors go unaddressed, the hormones will underperform.

The hormone–sex connection

Sexual function unfolds across a response cycle — desire, arousal, orgasm, and resolution — and hormones influence every phase of it. They set the background tone for libido, support the blood flow and tissue changes of arousal, and shape the brain chemistry that makes sex feel rewarding. When hormones drift out of range, any of those phases can falter.

What makes hormones a tool rather than the whole answer is that they share the stage with several other systems. The brain is the true center of sexual desire and response; without adequate mental stimulation, as Dr. Greenleaf puts it, “all the Viagra in the world will not function.” The autonomic nervous system matters just as much: sex lives in the parasympathetic “rest, digest, and heal” state, and chronic sympathetic activation — the body’s stress response — shunts blood and energy away from reproduction entirely. Stress, she notes, is the biggest killer of libido, and modern “lions” come in many forms: work, illness, poor diet, dehydration, gut imbalance, and toxins.

The practical takeaway is that sexual dysfunction is usually a symptom of a larger picture, not a standalone hormone problem. Optimizing hormones is genuinely useful — but it works best when the nervous system, lifestyle, vascular health, and psychological factors are addressed alongside it. The sections below walk through each major hormone, then through how they fit into a complete treatment plan.

Testosterone (men and women)

Testosterone is the hormone most associated with libido, and for good reason — it supports sexual desire, arousal, and energy in both men and women. It is not a male-only hormone; women produce and rely on testosterone too, and a decline can blunt drive and responsiveness in either sex.

In men, testosterone is one of the inputs evaluated whenever low libido or erectile difficulty is present, and a serum level is a routine part of the workup. But the connection is looser than patients assume. As the data Dr. Greenleaf presents make clear, many men with low measured testosterone are asymptomatic and report normal libido, while a considerable share of men with low libido have entirely normal testosterone. That is precisely why testosterone is assessed as one piece of a broader evaluation rather than treated as an automatic diagnosis. To understand the symptom side of that picture, see our overview of the signs of low testosterone.

When symptomatic deficiency is confirmed, replacement can improve libido, arousal, and energy in appropriately selected patients — but candidacy, testing, and monitoring all follow careful clinical criteria. The mechanics of who qualifies, how it is dosed, and how it is monitored are covered in depth in our companion guide to testosterone replacement therapy. In women, testosterone’s role in desire and arousal is real but more specialized; it is also applied locally in some cases of genital atrophy, which we return to below.

Estrogen (women)

For women, estrogen is central to the physical machinery of arousal. It maintains genital blood flow, natural lubrication, and the health of the vaginal and vulvar tissues. When estrogen falls — most often after menopause, but also with breastfeeding, certain cancer treatments, or anti-estrogen medications such as tamoxifen — those tissues thin, dry, and lose elasticity.

The result is genitourinary syndrome of menopause (GSM), formerly called atrophic vaginitis: dryness, irritation, and pain with intercourse that directly undermine arousal and comfort. Because GSM involves both vaginal and urinary tissue, it can also raise the risk of urinary tract infections. It is one of the most common — and most treatable — hormonal contributors to sexual difficulty in women. Our dedicated guide to vaginal dryness and GSM covers the condition in full.

Low-dose vaginal estrogen is an effective, well-studied treatment for these local symptoms. Because the dose is low and little estrogen enters the bloodstream, it carries a lower risk of systemic effects than oral or transdermal estrogen, though it is used with caution in women with a history of breast cancer and warrants individualized risk discussion. It can restore the vaginal mucosa, reduce painful intercourse, and improve sexual function and quality of life. How estrogen is selected, formulated, and monitored — systemically and locally — is the subject of our guide to estrogen replacement therapy.

DHEA and other sex steroids

Beyond testosterone and estrogen, DHEA deserves a place in any discussion of hormones and sexual function. DHEA is an upstream precursor the body can convert into both androgens and estrogens, which gives it a more localized, modulating role.

One area where the evidence is reasonably encouraging is vaginal DHEA for genital atrophy. Applied locally, it has been shown to improve the symptoms of vaginal atrophy — dryness, irritation, and painful intercourse — and to improve aspects of sexual function including desire, arousal, lubrication, orgasm, and satisfaction. Importantly, vaginal DHEA appears to act largely locally: it can raise circulating DHEA-S and testosterone modestly while keeping them within normal postmenopausal ranges, without clinically significant systemic effects at standard doses. The same is true of low-dose vaginal testosterone, which can similarly improve atrophy-related symptoms without meaningfully raising systemic levels.

Systemic DHEA has its own broader role in hormone optimization, and the candidacy, dosing, and monitoring details are best understood in context — see our guide to DHEA therapy. The exact concentrations, formulations, and titration of any of these local hormones are taught in Empire’s course rather than reproduced here.

Thyroid and cortisol

Not every hormonal contributor to sexual dysfunction is a sex steroid. Thyroid hormone and cortisol act on the system more indirectly, but they matter enough that both are commonly included in a sexual dysfunction workup. When a clinician orders labs for low libido, Dr. Greenleaf includes thyroid function and cortisol alongside testosterone and estrogen — a deliberately wide net, because the cause often sits outside the obvious place.

Thyroid dysfunction can depress energy, mood, and libido systemically; an under- or over-active thyroid changes the whole metabolic backdrop against which sexual desire operates. Cortisol is the more revealing one. As the body’s primary stress hormone, chronically elevated cortisol keeps the system locked in the sympathetic “fight-or-flight” state — the exact opposite of the relaxed, parasympathetic state that sexual function requires. This is the mechanism behind the principle that stress and sex cannot coexist, and it is why even well-dosed hormone therapy fails when stress is left unaddressed. You can replace a hormone, but you cannot out-dose a nervous system stuck in survival mode.

How hormones fit into sexual treatment

Put the pieces together and a practical sequence emerges. Optimize hormones first — identify and correct documented deficiencies in testosterone, estrogen, DHEA, or thyroid, and screen for the stress and cortisol picture that can undercut everything else. Hormone correction is often the foundation that makes other treatments work better.

But it is rarely the whole intervention. The most reliable outcomes come from combining hormone optimization with the other tools matched to the specific dysfunction — vascular treatments for erectile dysfunction, local therapies for GSM, behavioral and psychological care for desire and anxiety, and pelvic floor work where indicated. Hormones set the stage; the targeted therapy plays the scene.

One bridge worth highlighting is the peptide PT-141 (bremelanotide). Unlike a hormone, PT-141 works centrally — it acts on the brain’s melanocortin pathways and dopamine signaling to boost desire and arousal in both men and women, which makes it a useful complement when libido is the limiting problem rather than mechanics or tissue health. It is one of the clearer examples of how a non-hormonal agent can sit alongside hormone optimization rather than replace it. For the clinical detail, see our guide to PT-141.

Evaluation and monitoring

Because hormones are only one input, the evaluation has to be broad. A focused sexual dysfunction workup that takes hormones seriously typically includes a detailed medical and sexual history — onset, duration, severity, and especially sources of stress and inflammation — alongside a physical exam and targeted labs.

On the laboratory side, Dr. Greenleaf casts a wide net: testosterone, estrogen, thyroid function, cortisol, and other relevant markers, with additional testing (glucose, lipids, liver and kidney function, inflammatory markers) guided by what the history suggests. The reminder she emphasizes is to look outside the pelvis — diabetes, cardiovascular disease, herniated discs, brain pathology, past trauma, and lifestyle stressors can all drive sexual dysfunction while hormone levels look unremarkable.

Monitoring then follows whatever therapy is chosen: rechecking levels where systemic hormones are used, watching for the mild local effects (such as acne or hirsutism) that can accompany topical androgens, and reassessing symptoms and quality of life over time. The full testing logic, reference ranges, and monitoring schedules for hormone therapy live in our hormone replacement therapy pillar guide — the natural next read for the optimization side of this topic. Specific test panels, target ranges, and titration are taught in Empire’s courses rather than prescribed here.